Brain Targets & Leads

  Counts
Total Number Participants 377
Participants with Unilateral Leads 4
Participants with Bilateral Leads 360
Participants with Dual Leads 11
Total Number of DBS Leads 774
Total Number Explants 7
Target Participant Count Lead Count Explants
ALIC-NA 9 18
Anterior GPi 101 201
Ce-Spv-Voi 13 26
CM/PFc Thalamus 184 369 7
GPi 26 52
GPi+CMPF 1 2
Posterior GPi 53 106

Cases Where Multiple Targets Were Implanted

Targets Count of Patients
ALIC-NA Anterior GPi CM/PFc Thalamus Ce-Spv-Voi GPi GPi+CMPF Posterior GPi  
Y Y 0
Y Y Y 1
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y 3
Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y 0
Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y 0
Y Y 0
Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y 0
Y Y 4
Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y 0
Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y 0
Y Y 0
Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y 1
Y Y 0
Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y 1
Y Y 0
Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y 1
Y Y 0
Y Y 0
Y Y Y 0
Y Y Y 0
Y Y Y Y 0
Y Y Y 0
Y Y 0
Y Y 0
Y Y 0
Y Y Y 0
Y Y 0















Adverse Events Chart List


Timepoint
6 Month
All Targets ALIC-NAAnterior GPiCe-Spv-VoiCM/PFc ThalamusGPiGPi+CMPFPosterior GPi
  n ( 137 ) subjects ( 42 ) % {Total Cohort} n ( 0 ) subjects ( 0 ) % n ( 21 ) subjects ( 7 ) % n ( 0 ) subjects ( 0 ) % n ( 67 ) subjects ( 24 ) % n ( 0 ) subjects ( 0 ) % n ( 0 ) subjects ( 0 ) % n ( 59 ) subjects ( 14 ) %
Explants 1 1 2.38% 000.00%000.00%000.00%114.17%000.00%000.00%000.00%
Infections 2 2 4.76% 000.00%000.00%000.00%228.33%000.00%000.00%000.00%
Hemorrhages 2 2 4.76% 000.00%000.00%000.00%114.17%000.00%000.00%117.14%
Programming Related 112 34 80.95% 000.00%10342.86%000.00%441770.83%000.00%000.00%5814100.00%
Other Adverse Events 132 42 100.00% 000.00%217100.00%000.00%6324100.00%000.00%000.00%5814100.00%
Click to Show Other Adverse Events Details
 
All Targets
n ( # ) Number of adverse events by category (where # is total number of adverse events).
subjects ( # ) Number of subjects with an adverse event by category
(where # is total number of subjects with leads).
% {Total Cohort} Total number of leads with an adverse event out of total subjects.
Individual Target
n ( # ) Number of adverse events by category for the target (where # is total number of adverse events for the target).
subjects ( # ) Number of participants with an adverse event and the target by category
(where # is total number of participants with the target).
% Percent of total number of participants with the target by category.
Timepoint
1 Year
All Targets ALIC-NAAnterior GPiCe-Spv-VoiCM/PFc ThalamusGPiGPi+CMPFPosterior GPi
  n ( 158 ) subjects ( 49 ) % {Total Cohort} n ( 0 ) subjects ( 0 ) % n ( 22 ) subjects ( 7 ) % n ( 0 ) subjects ( 0 ) % n ( 79 ) subjects ( 29 ) % n ( 0 ) subjects ( 0 ) % n ( 0 ) subjects ( 0 ) % n ( 67 ) subjects ( 16 ) %
Explants 1 1 2.04% 000.00%000.00%000.00%113.45%000.00%000.00%000.00%
Infections 5 4 8.16% 000.00%000.00%000.00%5413.79%000.00%000.00%000.00%
Hemorrhages 2 2 4.08% 000.00%000.00%000.00%113.45%000.00%000.00%116.25%
Programming Related 129 38 77.55% 000.00%11342.86%000.00%521965.52%000.00%000.00%6616100.00%
Other Adverse Events 150 48 97.96% 000.00%227100.00%000.00%722896.55%000.00%000.00%6616100.00%
Click to Show Other Adverse Events Details
 
All Targets
n ( # ) Number of adverse events by category (where # is total number of adverse events).
subjects ( # ) Number of subjects with an adverse event by category
(where # is total number of subjects with leads).
% {Total Cohort} Total number of leads with an adverse event out of total subjects.
Individual Target
n ( # ) Number of adverse events by category for the target (where # is total number of adverse events for the target).
subjects ( # ) Number of participants with an adverse event and the target by category
(where # is total number of participants with the target).
% Percent of total number of participants with the target by category.
Timepoint
2 Year
All Targets ALIC-NAAnterior GPiCe-Spv-VoiCM/PFc ThalamusGPiGPi+CMPFPosterior GPi
  n ( 184 ) subjects ( 53 ) % {Total Cohort} n ( 0 ) subjects ( 0 ) % n ( 25 ) subjects ( 7 ) % n ( 0 ) subjects ( 0 ) % n ( 90 ) subjects ( 32 ) % n ( 0 ) subjects ( 0 ) % n ( 0 ) subjects ( 0 ) % n ( 79 ) subjects ( 17 ) %
Explants 6 5 9.43% 000.00%000.00%000.00%6515.62%000.00%000.00%000.00%
Infections 7 6 11.32% 000.00%000.00%000.00%7618.75%000.00%000.00%000.00%
Hemorrhages 2 2 3.77% 000.00%000.00%000.00%113.12%000.00%000.00%115.88%
Programming Related 152 42 79.25% 000.00%14342.86%000.00%612268.75%000.00%000.00%7717100.00%
Other Adverse Events 169 51 96.23% 000.00%257100.00%000.00%763093.75%000.00%000.00%7817100.00%
Click to Show Other Adverse Events Details
 
All Targets
n ( # ) Number of adverse events by category (where # is total number of adverse events).
subjects ( # ) Number of subjects with an adverse event by category
(where # is total number of subjects with leads).
% {Total Cohort} Total number of leads with an adverse event out of total subjects.
Individual Target
n ( # ) Number of adverse events by category for the target (where # is total number of adverse events for the target).
subjects ( # ) Number of participants with an adverse event and the target by category
(where # is total number of participants with the target).
% Percent of total number of participants with the target by category.
Timepoint
3 Year
All Targets ALIC-NAAnterior GPiCe-Spv-VoiCM/PFc ThalamusGPiGPi+CMPFPosterior GPi
  n ( 197 ) subjects ( 54 ) % {Total Cohort} n ( 0 ) subjects ( 0 ) % n ( 28 ) subjects ( 7 ) % n ( 0 ) subjects ( 0 ) % n ( 90 ) subjects ( 32 ) % n ( 0 ) subjects ( 0 ) % n ( 0 ) subjects ( 0 ) % n ( 89 ) subjects ( 18 ) %
Explants 7 6 11.11% 000.00%000.00%000.00%6515.62%000.00%000.00%115.56%
Infections 7 6 11.11% 000.00%000.00%000.00%7618.75%000.00%000.00%000.00%
Hemorrhages 2 2 3.70% 000.00%000.00%000.00%113.12%000.00%000.00%115.56%
Programming Related 165 43 79.63% 000.00%17342.86%000.00%612268.75%000.00%000.00%8718100.00%
Other Adverse Events 181 51 94.44% 000.00%287100.00%000.00%763093.75%000.00%000.00%871794.44%
Click to Show Other Adverse Events Details
 
All Targets
n ( # ) Number of adverse events by category (where # is total number of adverse events).
subjects ( # ) Number of subjects with an adverse event by category
(where # is total number of subjects with leads).
% {Total Cohort} Total number of leads with an adverse event out of total subjects.
Individual Target
n ( # ) Number of adverse events by category for the target (where # is total number of adverse events for the target).
subjects ( # ) Number of participants with an adverse event and the target by category
(where # is total number of participants with the target).
% Percent of total number of participants with the target by category.
Timepoint
4 Year
All Targets ALIC-NAAnterior GPiCe-Spv-VoiCM/PFc ThalamusGPiGPi+CMPFPosterior GPi
  n ( 218 ) subjects ( 57 ) % {Total Cohort} n ( 0 ) subjects ( 0 ) % n ( 36 ) subjects ( 7 ) % n ( 0 ) subjects ( 0 ) % n ( 93 ) subjects ( 34 ) % n ( 0 ) subjects ( 0 ) % n ( 0 ) subjects ( 0 ) % n ( 99 ) subjects ( 19 ) %
Explants 10 9 15.79% 000.00%000.00%000.00%7617.65%000.00%000.00%3315.79%
Infections 8 7 12.28% 000.00%000.00%000.00%8720.59%000.00%000.00%000.00%
Hemorrhages 2 2 3.51% 000.00%000.00%000.00%112.94%000.00%000.00%115.26%
Programming Related 184 45 78.95% 000.00%25342.86%000.00%632367.65%000.00%000.00%9619100.00%
Other Adverse Events 198 52 91.23% 000.00%367100.00%000.00%773191.18%000.00%000.00%951789.47%
Click to Show Other Adverse Events Details
 
All Targets
n ( # ) Number of adverse events by category (where # is total number of adverse events).
subjects ( # ) Number of subjects with an adverse event by category
(where # is total number of subjects with leads).
% {Total Cohort} Total number of leads with an adverse event out of total subjects.
Individual Target
n ( # ) Number of adverse events by category for the target (where # is total number of adverse events for the target).
subjects ( # ) Number of participants with an adverse event and the target by category
(where # is total number of participants with the target).
% Percent of total number of participants with the target by category.
Timepoint
5 Year
All Targets ALIC-NAAnterior GPiCe-Spv-VoiCM/PFc ThalamusGPiGPi+CMPFPosterior GPi
  n ( 270 ) subjects ( 65 ) % {Total Cohort} n ( 7 ) subjects ( 3 ) % n ( 51 ) subjects ( 7 ) % n ( 0 ) subjects ( 0 ) % n ( 108 ) subjects ( 41 ) % n ( 0 ) subjects ( 0 ) % n ( 0 ) subjects ( 0 ) % n ( 119 ) subjects ( 19 ) %
Explants 13 12 18.46% 1133.33%000.00%000.00%10921.95%000.00%000.00%3315.79%
Infections 13 12 18.46% 2266.67%000.00%000.00%121126.83%000.00%000.00%000.00%
Hemorrhages 2 2 3.08% 000.00%000.00%000.00%112.44%000.00%000.00%115.26%
Programming Related 235 52 80.00% 73100.00%40342.86%000.00%772970.73%000.00%000.00%11619100.00%
Other Adverse Events 242 59 90.77% 43100.00%517100.00%000.00%853790.24%000.00%000.00%1151789.47%
Click to Show Other Adverse Events Details
 
All Targets
n ( # ) Number of adverse events by category (where # is total number of adverse events).
subjects ( # ) Number of subjects with an adverse event by category
(where # is total number of subjects with leads).
% {Total Cohort} Total number of leads with an adverse event out of total subjects.
Individual Target
n ( # ) Number of adverse events by category for the target (where # is total number of adverse events for the target).
subjects ( # ) Number of participants with an adverse event and the target by category
(where # is total number of participants with the target).
% Percent of total number of participants with the target by category.